AlphAIAlphAI — Financial news for AI agents
investing.comOCT 232 min read$ABT

Abbott’s colorectal cancer test shows improved sensitivity

Abbott (NYSE: ABT) presented data at the European Society for Medical Oncology Congress showing its Oncodetect test for colorectal cancer recurrence achieved 72.2% sensitivity, outperforming its previous version. The study analyzed 279 patients, detecting additional cases with the new test. Patients with detectable ctDNA had higher recurrence risk and lower survival rates. The test is not FDA-approved and is performed at Genomic Health Inc.

Original reporting
investing.com
Published Oct 23, 2026, 1:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 1:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$ABT
Bullish
high confidence
Mentioned
$ABT
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ABTBullishMed
01

Why it matters

The disclosed sensitivity could position Abbott as a leader in colorectal cancer MRD testing, influencing future earnings and partnership opportunities.

02

Market read

First‑time release of significant clinical data for Abbott's colorectal cancer test, with potential upside for its diagnostics business.

03

What to watch

Reimbursement landscape and competition from other ctDNA tests could temper market reaction.

Relevance 8/10Novelty 8/10Timing: today

Background

Abbott's Oncodetect test is part of its broader push into molecular diagnostics; the data were presented at the European Society for Medical Oncology Congress.

Company-level read

Ticker impact

$ABTBullishHigh confidence
Context

Abbott presented new Oncodetect whole-genome sequencing test data showing 72.2% sensitivity for colorectal cancer recurrence, a first‑time disclosure of clinical performance.

Expected impact

potential upside as investors price in future regulatory approval and market adoption of the test

Evidence & confidence

The disclosed sensitivity improvement is material for Abbott's diagnostics segment and could drive share price if clearance is pursued.

Market effects

Sector

Strengthens the liquid‑biopsy and oncology diagnostics sector, may spur competitor R&D and affect valuation of similar biotech firms.

Regional

U.S. and Japanese markets may see modest interest due to the collaboration with National Cancer Center Hospital East.

Global

Adds to global momentum in precision oncology diagnostics, potentially influencing investor sentiment toward healthcare innovation.

Counterpoint

What could challenge this read

If FDA clearance is delayed or denied, the data may not translate into revenue, limiting upside.

Key entities

  • Company
    Abbott Laboratories

    US‑listed healthcare company presenting the new test data.

  • Institution
    National Cancer Center Hospital East

    Japanese hospital collaborating on the study.

Read at source← All news

StoryAbbott reports 30‑percentage‑point sensitivity boost for Oncodetect colorectal cancer MRD test

Also covered by

2 outlets

Related articles

OCT 23
$ABTMedAI 8/10

Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer

Abbott (NYSE: ABT) presented data at ESMO 2026 showing its Oncodetect® test improved sensitivity for detecting colorectal cancer recurrence by 30% compared to its previous test. The study found a 10.6-fold higher recurrence risk for patients with detectable ctDNA. Abbott aims to connect innovations across cancer care, from early detection to post-treatment monitoring.

prnewswire.com2 min
OCT 22
$ABTMed

ABT Maintained by RBC Capital -- Price Target Lowered to $125

RBC Capital maintained an 'Outperform' rating on Abbott Laboratories (ABT) but lowered its price target from $130 to $125. GuruFocus values ABT at $135.74, suggesting a 24.9% undervaluation. The company has a GF Score of 82/100, indicating strong financial health and growth potential, but insiders have sold $46.85M in shares over the past three months.

gurufocus.com2 min
OCT 22
$ABTMed

Abbott plans nutrition spinoff as Q3 sales improve

Abbott plans to spin off its nutrition division by the end of 2027. Q3 sales improved 5.1% to $2.26B, but YTD sales fell 1.3%. The new company will include brands like Ensure and Similac, with 16,000 employees. Abbott's CEO cited changing consumer preferences as a driver for the separation.

nutraingredients.com2 min
OCT 22
$ABTMedAI 8/10

Mizuho reiterates Neutral on Abbott Labs stock, keeps $115 target

Mizuho maintained a Neutral rating and $115 target for Abbott Labs (ABT), citing segment challenges and operational headwinds. ABT reported Q3 2026 earnings of $1.42 per share, meeting estimates, with revenue at $13.01B. The company lowered full-year sales guidance and plans to spin off its Nutrition business by 2027. BTIG cut its target to $125 but kept a Buy rating.

investing.com2 min
OCT 22
$ABTMed

Abbott to spin-off nutrition into standalone business

Abbott Laboratories plans to spin off its nutrition business, which has $8.5bn in annual sales, into a standalone publicly traded company by the end of 2027. The move aims to address different investment profiles and growth strategies. Abbott's Q3 and nine-month results show a 1.3% decline in nutrition sales but a 11.9% increase in total group sales. The company recently settled lawsuits related to infant formula recalls for $385m and $670m.

finance.yahoo.com2 min